Sef downregulation by ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation

Cancer Research

Volumn 72, Issue 3, 2012, Pages 626-635

  Duhamel, Stéphanie ^a,b   Heb́ert, Joseé ^a,b,c   Gaboury, Louis ^a,b   Bouchard, Ameĺie ^d   Simon, Ronald ^e   Sauter, Guido ^e   Basik, Mark ^d   Meloche, Sylvain ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; RAS PROTEIN; REGULATOR PROTEIN; SEF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL NUCLEUS; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; COLON CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; MALIGNANT TRANSFORMATION; NUCLEAR LOCALIZATION SIGNAL; POLYPLOIDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; KARYOTYPING; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NIH 3T3 CELLS; PHOSPHORYLATION; POLYPLOIDY; RAS PROTEINS; RATS; RECEPTORS, INTERLEUKIN;

EID: 84856529117     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2126     Document Type: Article

References (40)

1. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007;26:3227-39. (Pubitemid 46763017)
2. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000;22:818-26.
3. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009;16:368-77.
4. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. Cosmic 2005. Br J Cancer 2006;94:318-22. (Pubitemid 43151554)
5. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
6. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009;15:294-303.
7. Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev 2009;19:4-11.
8. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65. (Pubitemid 37328850)
9. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308. (Pubitemid 46480970)
10. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-84. (Pubitemid 28222141)
11. Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 2005;1756:115-25.
12. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-20. (Pubitemid 37040827)
13. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007;26:3100-12. (Pubitemid 46763006)
14. Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J Cell Sci 2005;118:2997-3002. (Pubitemid 41149904)
15. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006;31:268-75. (Pubitemid 43674354)
16. Zehorai E, Yao Z, Plotnikov A, Seger R. The subcellular localization of MEKand ERK - a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol 2010;314:213-20.
17. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-74. (Pubitemid 29057251)
18. Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B, et al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 2001;1:239-50. (Pubitemid 33653059)
19. Glading A, Koziol JA, Krueger J, Ginsberg MH. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007;67:1536-44. (Pubitemid 46383377)
20. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, et al. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 2008;8:337.
21. Perreault N, Jean-Francois B. Use of the dissociating enzyme thermolysin to generate viable human normal intestinal epithelial cell cultures. Exp Cell Res 1996;224:354-64. (Pubitemid 26140569)
22. Rodier G, Makris C, Coulombe P, Scime A, Nakayama K, Nakayama KI, et al. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2. J Cell Biol 2005;168:55-66. (Pubitemid 40111057)
23. Adachi M, Fukuda M, Nishida E. Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 2000;148:849-56.
24. Fukuda M, Gotoh I, Gotoh Y, Nishida E. Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J Biol Chem 1996;271:20024-8. (Pubitemid 26281751)
25. Jaaro H, Rubinfeld H, Hanoch T, Seger R. Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc Natl Acad Sci U S A 1997;94:3742-7. (Pubitemid 27180443)
26. Quaroni A, Wands J, Trelstad RL, Isselbacher KJ. Epithelioid cell cultures from rat small intestine: Characterization by morphologic and immunologic criteria. J Cell Biol 1979;80:248-65. (Pubitemid 9091502)
27. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005;437:1043-7. (Pubitemid 41486987)
28. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 2004;7:33-44. (Pubitemid 39172686)
29. Tolwinski NS, Shapiro PS, Goueli S, Ahn NG. Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression. Requirement for phosphorylation at the activation lip and signaling downstream of MKK. J Biol Chem 1999;274:6168-74. (Pubitemid 29111024)
30. Yao Z, Flash I, Raviv Z, Yung Y, Asscher Y, Pleban S, et al. Non-regulated and stimulated mechanisms cooperate in the nuclear accumulation of MEK1. Oncogene 2001;20:7588-96. (Pubitemid 33111859)
31. Burack WR, Shaw AS. Live Cell Imaging of ERK and MEK: simple binding equilibrium explains the regulated nucleocytoplasmic distribution of ERK. J Biol Chem 2005;280:3832-7. (Pubitemid 40223853)
32. Chuderland D, Konson A, Seger R. Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell 2008;31:850-61.
33. Lee SH, Lee JW, Soung YH, Kim SY, Nam SW, Park WS, et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 2004;112:233-8.
34. Furthauer M, Lin W, Ang SL, Thisse B, Thisse C. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol 2002;4:170-4. (Pubitemid 34141485)
35. Tsang M, Friesel R, Kudoh T, Dawid IB. Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 2002;4:165-9. (Pubitemid 34141484)
36. Darby S, Murphy T, Thomas H, Robson CN, Leung HY, Mathers ME, et al. Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. Br J Cancer 2009;101:1891-9.
37. Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010;220:452-60.
38. Zisman-Rozen S, Fink D, Ben-Izhak O, Fuchs Y, Brodski A, Kraus MH, et al. Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas. Oncogene 2007;26:6093-8. (Pubitemid 47373804)
39. Fukuda M, Gotoh I, Adachi M, Gotoh Y, Nishida E. A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J Biol Chem 1997;272:32642-8. (Pubitemid 28011955)
40. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007;17:157-62. (Pubitemid 46551722)